PDCD1 and neoplasm: This study also found that neoadjuvant PD-1 monoclonal antibody therapy enhanced chemokine transcript expressions, increased immune cell infiltration, enhanced TCR clone diversity of tumour-infiltrating T lymphocytes and enhanced local immune regulation (80).